宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

休市中 08-23 16:08:27

8.960

+0.670

+8.08%

最高9.800	最低8.310	成交量74.74万
今开8.800	昨收8.290	日振幅17.97%
总市值33.52亿	流通市值20.52亿	总股本3.74亿
成交额678.86万	换手率0.33%	流通股本2.29亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":8.96,"timestamp":1724400507028,"preClose":8.29,"halted":0,"volume":747400,"delay":0,"floatShares":229000000,"shares":374157695,"eps":-1.1492798,"marketStatus":"休市中","marketStatusCode":7,"change":0.67,"latestTime":"08-23 16:08:27","open":8.8,"high":9.8,"low":8.31,"amount":6788642,"amplitude":0.179735,"askPrice":8.96,"askSize":4000,"bidPrice":8.95,"bidSize":10200,"shortable":3,"etf":0,"ttmEps":-1.1492798668828892,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"listingDate":1693843200000,"adjPreClose":8.29,"openAndCloseTimeList":[[1724376600000,1724385600000],[1724389200000,1724400000000]],"volumeRatio":7.772462572903704,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541/tweets","defaultTab":"tweets","newsList":[{"id":"2461534526","title":"港股异动 | 宜明昂科-B(01541)现涨超18% 公司已自SynBioTx收取1000万美元的首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2461534526","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461534526?lang=zh_cn&edition=full","pubTime":"2024-08-23 14:31","pubTimestamp":1724394686,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B(01541)现涨超18%，截至发稿，涨13.03%，报9.37港元，成交额524.02万港元。消息面上，宜明昂科发布公告，公司根据授权及合作协议已自SynBioTx收取1000万美元的首付款。根据授权及合作协议，公司预计未来将收取不超过4000万美元的潜在近期付款，其中最早的一笔预计将于2024年9月收到。据悉，公司本月初公布，与SynBioTx订立授权及合作协议，公司同意授予SynBioTx在大中华地区以外研究、开发及商业化若干靶向程序性细胞死亡配体1及血管内皮生长因子的双特异性抗体以及若干靶向细胞毒性T淋巴细胞相关蛋白4的单克隆抗体的独家授权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1169190.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2461092535","title":"宜明昂科-B(01541)上涨14.48%，报9.49元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2461092535","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461092535?lang=zh_cn&edition=full","pubTime":"2024-08-23 13:42","pubTimestamp":1724391743,"startTime":"0","endTime":"0","summary":"8月23日，宜明昂科-B(01541)盘中上涨14.48%，截至13:42，报9.49元/股，成交196.16万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报，宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。8月26日，宜明昂科-B将披露2024财年中报。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/23134242645604.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2461347890","title":"宜明昂科－Ｂ(01541.HK)收到SynBioTx首付款1,000万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461347890","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461347890?lang=zh_cn&edition=full","pubTime":"2024-08-23 00:01","pubTimestamp":1724342460,"startTime":"0","endTime":"0","summary":"宜明昂科－Ｂ(01541.HK) 公布，根据授权及合作协议，已收到SynBioTx首付款1,000万美元。预计未来将收取不超过4,000万美元的潜在近期付款，其中最早的一笔预计将于9月收到。根据协议，公司授予SynBioTx在大中华地区（包括内地、香港、澳门及台湾）以外研究、开发及商业化若干靶向程序性细胞死亡配体1及血管内皮生长因子的双特异性抗体以及若干靶向细胞毒性T淋巴细胞相关蛋白4的单克隆抗体的独家授权。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1374229/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2461394948","title":"宜明昂科-B(01541)根据授权及合作协议自SynBioTx收取1000万美元的首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2461394948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461394948?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:37","pubTimestamp":1724323021,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B(01541)发布公告，公司根据授权及合作协议已自SynBioTx收取1000万美元的首付款。根据授权及合作协议，公司预计未来将收取不超过4000万美元的潜在近期付款，其中最早的一笔预计将于2024年9月收到。此外，公司与SynBioTx已成立联合临床开发与运营委员会，将积极推动IMM2510及IMM27M的开发。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1168612.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2461168357","title":"宜明昂科－Ｂ(01541)股价下跌8.886%，现价港币$8.1","url":"https://stock-news.laohu8.com/highlight/detail?id=2461168357","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461168357?lang=zh_cn&edition=full","pubTime":"2024-08-22 14:34","pubTimestamp":1724308440,"startTime":"0","endTime":"0","summary":"[下跌股]宜明昂科－Ｂ(01541) 股价在下午02:34比前收市价下跌8.886%，现股价为港币$8.1。至目前为止，今日最高价为$9.09，而最低价为$8.1。总成交量为9.06万股，总成交金额为港币$77.472万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725131627024_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2408221679/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2459287251","title":"宜明昂科-B(01541.HK)拟8月26日举行董事会会议审批中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2459287251","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459287251?lang=zh_cn&edition=full","pubTime":"2024-08-14 18:15","pubTimestamp":1723630520,"startTime":"0","endTime":"0","summary":"格隆汇8月14日丨宜明昂科-B(01541.HK)公告，公司将于2024年8月26日(星期一)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2024年6月30日止6个月的中期业绩及其刊发，并考虑建议派发中期股息(如有)。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814181520af97601a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240814181520af97601a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2459923563","title":"宜明昂科－Ｂ(01541)股价下跌5.323%，现价港币$9.96","url":"https://stock-news.laohu8.com/highlight/detail?id=2459923563","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459923563?lang=zh_cn&edition=full","pubTime":"2024-08-13 15:59","pubTimestamp":1723535940,"startTime":"0","endTime":"0","summary":"[下跌股]宜明昂科－Ｂ(01541) 股价在下午03:59比前收市价下跌5.323%，现股价为港币$9.96。至目前为止，今日最高价为$10.5，而最低价为$9.96。总成交量为18.36万股，总成交金额为港币$185.784万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180725133905145_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2408131168/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2459928496","title":"宜明昂科-B(01541)下跌5.13%，报9.98元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2459928496","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459928496?lang=zh_cn&edition=full","pubTime":"2024-08-13 15:52","pubTimestamp":1723535543,"startTime":"0","endTime":"0","summary":"8月13日，宜明昂科-B(01541)盘中下跌5.13%，截至15:52，报9.98元/股，成交182.57万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报，宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/13155242308277.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2458253090","title":"宜明昂科-B(01541)下跌5.12%，报10.38元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2458253090","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2458253090?lang=zh_cn&edition=full","pubTime":"2024-08-09 15:48","pubTimestamp":1723189731,"startTime":"0","endTime":"0","summary":"8月9日，宜明昂科-B(01541)盘中下跌5.12%，截至15:48，报10.38元/股，成交213.63万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报，宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/09154842210517.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2457003895","title":"宜明昂科-B(01541)下跌5.3%，报11.8元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2457003895","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457003895?lang=zh_cn&edition=full","pubTime":"2024-08-07 15:44","pubTimestamp":1723016683,"startTime":"0","endTime":"0","summary":"8月7日，宜明昂科-B(01541)盘中下跌5.3%，截至15:44，报11.8元/股，成交431.02万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报，宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/07154442137118.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"1189451748","title":"异动解读 | 宜明昂科-B盘中大跌8.18%,市场关注公司基本面","url":"https://stock-news.laohu8.com/highlight/detail?id=1189451748","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189451748?lang=zh_cn&edition=full","pubTime":"2024-08-05 10:08","pubTimestamp":1722823703,"startTime":"0","endTime":"0","summary":"8月5日,宜明昂科-B股价在盘中出现大幅下跌,跌幅达8.18%,引发市场广泛关注。宜明昂科是一家以科研为导向的生物技术公司,主要致力于开发肿瘤免疫疗法。不过,分析人士指出,尽管该交易为公司带来可观收益,但也可能引发市场对公司基本面的担忧。一方面,公司2023年年报显示营收和净利润均出现大幅下滑,业绩表现不佳;另一方面,公司在研管线产品虽具有创新性,但仍处于临床阶段,未来商业化前景存在不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541"],"gpt_icon":0},{"id":"2457762096","title":"宜明昂科-B(01541)下跌5.5%，报14.1元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2457762096","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457762096?lang=zh_cn&edition=full","pubTime":"2024-08-05 09:58","pubTimestamp":1722823101,"startTime":"0","endTime":"0","summary":"8月5日，宜明昂科-B(01541)盘中下跌5.5%，截至09:58，报14.1元/股，成交220.55万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报，宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/05095842037678.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2457657997","title":"BD新贵:宜明昂科-B(01541)和他的差异化创新力","url":"https://stock-news.laohu8.com/highlight/detail?id=2457657997","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2457657997?lang=zh_cn&edition=full","pubTime":"2024-08-05 08:35","pubTimestamp":1722818118,"startTime":"0","endTime":"0","summary":"8月2日，宜明昂科股价大幅高开，最高涨幅达52.78%，交投活跃。此次超20亿美元BD合作对宜明昂科后续增长的推动作用不言而喻。国际业界同行看中宜明昂科IMM2510和IMM27M的主要原因在于这两款产品在治疗与全球商业化方面存在不断被深掘的巨大价值。反之，赛道内诸如宜明昂科这类拥有自有研发引擎的biotech有望通过产品的差异化创新实现弯道超车。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1159755.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2456547690","title":"宜明昂科向Instil Bio授权两款产品，困境中的两家明星公司抱团取暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2456547690","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456547690?lang=zh_cn&edition=full","pubTime":"2024-08-02 16:46","pubTimestamp":1722588367,"startTime":"0","endTime":"0","summary":"合作收益方面，宜明昂科将获得5000万美元的首付款以及潜在近期付款。截至发稿时，宜明昂科涨超7%。当前，宜明昂科和Instil Bio公司的合作也落在了CD47之外的在研产品上。Instil Bio公司其实是前两年的明星公司。在上市首日，Instil Bio的市值突破了30亿美元，而这也是它的巅峰时刻。Instil Bio公司昔日的名气来源于ITIL-168。财务数据显示，截至今年一季度末，Instil Bio公司拥有现金、现金等价物、有价证券和长期投资1.615亿美元，其中现金和现金等价物部分是550万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080216491295774f5b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024080216491295774f5b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4505","BK4139","TIL","01541"],"gpt_icon":0},{"id":"2456403714","title":"港股异动丨宜明昂科一度飙升52% 授产品大中华区以外开发及商业化权利宜明昂科-B(1541.HK)今日逆势上涨，盘初一度飙升52.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456403714","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456403714?lang=zh_cn&edition=full","pubTime":"2024-08-02 13:35","pubTimestamp":1722576906,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2456482944","title":"宜明昂科-B(01541)上涨9.86%，报15.82元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2456482944","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456482944?lang=zh_cn&edition=full","pubTime":"2024-08-02 10:58","pubTimestamp":1722567530,"startTime":"0","endTime":"0","summary":"8月2日，宜明昂科-B(01541)盘中上涨9.86%，截至10:58，报15.82元/股，成交4007.17万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2023年年报，宜明昂科-B营业总收入38.6万元、净利润-3.79亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/08/02105841987572.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2456412198","title":"恒生医疗保健指数升1.7% 宜明昂科(01541)涨超18.8% 上海印发《关于支持生物医药产业全链条创新发展的若干意见》","url":"https://stock-news.laohu8.com/highlight/detail?id=2456412198","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456412198?lang=zh_cn&edition=full","pubTime":"2024-08-02 10:14","pubTimestamp":1722564882,"startTime":"0","endTime":"0","summary":"消息面上，7月30日上海市人民政府办公厅印发《关于支持生物医药产业全链条创新发展的若干意见》，并召开发布会详细解读，文件内容公布8方面的37项政策举措。中邮证券表示，此次上海发布《意见》，明确支持基因与细胞治疗、mRNA、合成生物、再生医学等前沿赛道，支持人工智能技术赋能药物研发。","market":"nz","thumbnail":"https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20200908/YzIxOTk5NDIxODE3ODE=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1941547","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02511","09995","BK1600","BK1100","02172","BK1161","159506","03347","161726","02157","BK1576","LU1969619763.USD","09966","01541","BK1141","BK1574","399441","BK1583","01302","LU2328871848.SGD","01244"],"gpt_icon":0},{"id":"2456541972","title":"宜明昂科-B早盘大涨25% 就两款癌症创新药达成授权合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2456541972","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456541972?lang=zh_cn&edition=full","pubTime":"2024-08-02 09:44","pubTimestamp":1722563040,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　宜明昂科-B（01541）早盘高开，股价上涨25%，现报18港元，成交额1628.38万港元。\n　　宜明昂科公布，与SynBioTx订立授权及合作协议，公司同意授予SynBioTx在大中华地区以外研究、开发及商业化若干靶向程序性细胞死亡配体1及血管内皮生长因子的双特异性抗体以及若干靶向细胞毒性T淋巴细胞相关蛋白4的单克隆抗体的独家授权。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-02/doc-inchfezm4051607.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-08-02/doc-inchfezm4051607.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK1161","BK1574","01541","159992"],"gpt_icon":0},{"id":"2456194994","title":"【港股通】宜明昂科(01541)大涨37% 与SynBioTx订立授权及合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2456194994","media":"金吾财讯","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456194994?lang=zh_cn&edition=full","pubTime":"2024-08-02 09:40","pubTimestamp":1722562851,"startTime":"0","endTime":"0","summary":"金吾财讯 | 宜明昂科(01541)早盘股价逆市冲高，截至发稿，报19.82港元，涨幅37.64%，成交额906.19万港元。消息面上，与SynBioTx订立授权及合作协议，公司同意授予SynBioTx在大中华地区以外研究、开发及商业化若干靶向程序性细胞死亡配体1及血管内皮生长因子的双特异性抗体以及若干靶向细胞毒性T淋巴细胞相关蛋白4的单克隆抗体的独家授权。根据协议，公司将收取不超过5,000万美元的首付款及潜在近期付款，以及不超过21亿美元的商业、开发及监管里程碑付款，另收取按大中华地区以外全球销售净额的个位数至低两位数比例计算的特许权使用费。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/MDI1YTMwZTQxYzhhNDE2OTgwYTUxYmYyODYyMzUwODkzNDM3NDk5.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MDI1YTMwZTQxYzhhNDE2OTgwYTUxYmYyODYyMzUwODkzNDM3NDk5.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1941542","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","YANG","01541","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2456415771","title":"【港股异动 | 宜明昂科-B(01541.HK)高开逾11% 就两款癌症创新药达成授权合作 总金额超20亿美元】智通财经APP获悉，宜明昂科-B(01541.","url":"https://stock-news.laohu8.com/highlight/detail?id=2456415771","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456415771?lang=zh_cn&edition=full","pubTime":"2024-08-02 09:22","pubTimestamp":1722561759,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","01541","BK1574","159992","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0417},{"period":"1month","weight":-0.3},{"period":"3month","weight":-0.3863},{"period":"6month","weight":-0.6195},{"period":"1year","weight":-0.5183},{"period":"ytd","weight":-0.7003}],"compareEarnings":[{"period":"1week","weight":0.0104},{"period":"1month","weight":0.0174},{"period":"3month","weight":-0.0536},{"period":"6month","weight":0.053},{"period":"1year","weight":-0.0329},{"period":"ytd","weight":0.0331}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事测试生物技术研发的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}